4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibitor, is being developed for the treatment of adult patients with moderate to severe alopecia areata. In light of the FDA approval of a different JAK inhibitor as the first treatment for alopecia areata, the FDA previously notified Concert that it was reviewing the Breakthrough Therapy designation previously granted for deuruxolitinib. At the FDA's request, Concert submitted additional clinical data an

Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sales M

Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sale

New Analyses Presented on the Effect of Baseline Severity and Duration of Current Episode of Hair Loss on Scalp Hair Regrowth Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the presentation of data from its THRIVE-AA1 Phase 3 clinical trial during the 12th World Congress for Hair Research. The presentation highlights THRIVE-AA1 study results evaluating Concert's investigational oral medicine deuruxolitinib (CTP-543) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss. The World Congress presentation includes new analyses from THRIVE‑AA1 showing the effect of deuruxolitinib on regrowth of scalp hai

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT. A webcast of the presentation may be accessed in the Investors section of the Company's website at www.concertpharma.com. A replay will be available on Concert's website for two weeks following the presentation. About Concert Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib (CTP-543), a novel, deuterated, oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with deuruxolitinib in adults with alopecia areata, a serious

Company Plans to Submit NDA in First Half of 2023 for Deuruxolitinib in Adults with Moderate to Severe Alopecia Areata Deuruxolitinib (CTP-543) Phase 3 Data Presented at the EADV Congress Late Breaking News Session Additional Deuruxolitinib Phase 3 Results to be Presented at the World Congress for Hair Research Conference Call Scheduled Today at 8:30 a.m. ET; Registration Required to Join Live Call Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the third quarter of 2022. "With the THRIVE-AA clinical program completed and positive Phase 3 results in hand for deuruxolitinib in alopecia areata, we are well on our way to meeting our goal of submitting the

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its third quarter 2022 financial results and provide a business update. To join the live call to ask questions, please register here. A dial in and unique PIN will be provided to join the call. An audio-only webcast of the call may be accessed in the Investors section of the Company's website at www.concertpharma.com. A replay of the webcast will be available on Concert's website for three months. About Concert

35 Percent of Patients Treated With CTP-543 12 mg Twice-Daily Achieved At Least 90 Percent Scalp Hair Coverage (SALT Score ≤ 10) After 24 Weeks of Treatment Newly-Reported Results Show Significant Improvement in Eyebrow and Eyelash Regrowth in Patients Treated With Both Doses of CTP-543 Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the presentation of data from its Phase 3 clinical trial, THRIVE-AA1. The presentation highlights THRIVE-AA1 study results evaluating Concert's oral investigational medicine CTP-543 in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss. The THRIVE-AA1 data are being pre

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022. The on-demand webcast of the presentation may be accessed in the Investors section of the Company's website at www.concertpharma.com. A replay of the webcast will be available on Concert's website for two weeks following the presentation. About Concert Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing CTP-543, a novel oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with CT

September is Alopecia Areata Awareness Month Alopecia Areata is a Serious Autoimmune Disorder with Limited Treatment Options In recognition of Alopecia Areata Awareness Month, bridges, buildings and other landmarks across the United States will be illuminated blue to raise awareness for this serious autoimmune disease. The effort will unite U.S. cities in observance of Alopecia Areata Awareness Month, which is recognized annually during September. The current illumination schedule follows below. Any updates or additions to the schedule will be posted here. If you plan to visit an illumination, we invite you to take a photo and tag your social media postings with the hashtag: #LightItUpBl

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has been appointed to its Board of Directors effective March 18, 2021. Ms. Stuart is Chief Operating Officer at Concert Pharmaceuticals Inc. (NASDAQ: CNCE) and is a leader in strategic planning, business operations and business development in the biopharmaceutical and biotechnology industries. “We are pleased to welcome Nancy to our Board of Directors. Her experience at a broad range of companies from both a

SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

JonesTrading analyst Sean Kim downgrades Concert Pharma (NASDAQ:CNCE) from Buy to Hold.

Gainers Genius Group Limited (NYSE:GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed Timothy Murphy to lead Illegal Trading Task Force. NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) gained 87% to $2.34 after the company reported final results from its Alzheimer's biomarker study. Amesite Inc. (NASDAQ:AMST) climbed 63% to $0.43. Gorilla Technology Group Inc. (NASDAQ:GRRR) shares surged 42.8% to $7.97. Gorilla Technology Group completed the acquisition of the tech stack of SeeQuestor Limited. XORTX Therapeutics Inc. (NASDAQ:XRTX) gained 32% to $1.03 after the company announced topline results from the XRX-OXY-101 clinical trial. Cuentas Inc. (NASDAQ

Gainers BeyondSpring (NASDAQ:BYSI) stock moved upwards by 24.4% to $2.7 during Thursday's regular session. Trading volume for BeyondSpring's stock is 1.2 million as of 12:30 EST. This is 132.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $105.1 million. Concert Pharma (NASDAQ:CNCE) shares rose 20.28% to $8.3. The current volume of 44.2 million shares is 9544.2% of Concert Pharma's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $397.8 million. Bellicum Pharmaceuticals (NASDAQ:BLCM) shares moved upwards by 17.93% to $1.25. Bellicum Pharmaceuticals's stock is trading

U.S. stocks traded lower, with the Dow Jones dropping around 200 points on Thursday. Here are some big stocks recording gains in today’s session. Gorilla Technology Group Inc. (NASDAQ:GRRR) shares jumped 42.8% to $7.97. Gorilla Technology Group completed the acquisition of the tech stack of SeeQuestor Limited. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) shares rose 20.2% to $8.30 after Sun Pharma announced it will acquire the company. AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) gained 15.7% to $10.30. EHang Holdings Limited (NASDAQ:EH) jumped 15.4% to $13.07. New Oriental Education & Technology Group Inc. (NYSE:EDU) surged 12.5% to $45.72. New Oriental Education & Technology Gr

U.S. stocks traded lower this morning, with the Dow Jones dropping around 200 points on Thursday. Following the market opening Thursday, the Dow traded down 0.62% to 33,090.82 while the NASDAQ fell 0.70% to 10,880.01. The S&P 500 also fell, dropping, 0.64% to 3,903.72. Check This Out: Ethereum Drops Below This Key Level; Gala Becomes Top Loser Leading and Lagging Sectors Real estate shares rose by 0.5% on Thursday. Meanwhile, top gainers in the sector included The Real Brokerage Inc. (NASDAQ:REAX), up 6%, and KE Holdings Inc. (NYSE:BEKE), up 2%. In trading on Thursday, financials shares dipped by 1.4%. Top Headline US initial jobless claims dropped by 15,000 from the prior week to 1

Sun Pharmaceutical Industries Limited, India's top pharmaceutical company, has agreed to acquire Concert Pharmaceuticals Inc (NASDAQ:CNCE) for an upfront payment of $8.00 per share, or $576 million in equity value. Concert stockholders will also receive a non-tradeable contingent value right (CVR) entitling holders to receive up to an additional $3.50 per share in cash, payable upon deuruxolitinib achieving certain net sales milestones within specified periods. Concert is a late-stage biotechnology company, with its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for Alopecia Areata, an autoimmune dermatological disease characterized by patchy hai